MICROWAVE ABLATION
FOR KIDNEY CANCER (RCC)

Most kidney cancers are now detected incidentally on imaging done for other reasons — meaning many patients have small, asymptomatic tumours when diagnosed. For these "small renal masses" (typically <4 cm), the treatment goal shifts from aggressive radical surgery to balanced approaches that achieve cancer control while preserving kidney function. Microwave ablation is part of this nephron-sparing toolkit.

“A small renal mass in an older patient with hypertension, diabetes, and reduced kidney function is a very different clinical problem than a large tumour in a young healthy patient. Ablation belongs to the first scenario.”

• The Nephron-Sparing Philosophy

  Every patient has limited kidney functional reserve. Each nephron lost increases the risk of chronic kidney disease, cardiovascular disease, and dialysis dependence over time. MWA destroys only the tumour and a small margin, preserving all other nephrons — critical for patients with single kidney, prior nephrectomy, or pre-existing kidney disease.

• Better Tolerated in Older or Sicker Patients

  Partial nephrectomy, while typically curative, requires general anaesthesia and surgical recovery. For older patients with cardiac disease, COPD, or significant frailty, the procedural risk of surgery may outweigh the cancer benefit — particularly for small slow-growing tumours. MWA offers similar cancer control with substantially less procedural stress.

Patient selection drives outcomes. MWA is well-suited to specific patient profiles where the benefits clearly outweigh the small disadvantages compared to surgery.

• T1a RCC (Tumours <4 cm) in Non-Surgical Candidates

  Patients with small renal masses who are not optimal candidates for partial nephrectomy — older age, significant cardiac or pulmonary disease, frailty, or other major comorbidities. MWA offers curative-intent treatment with substantially less procedural risk than surgery.

• Single Kidney or Bilateral Disease

  Patients with only one functional kidney (prior nephrectomy, congenital, or non-functional contralateral kidney) or bilateral RCC face high stakes — kidney loss would mean dialysis. MWA's nephron-sparing precision is particularly valuable here, even in patients who could otherwise tolerate surgery.

• Hereditary Kidney Cancer Syndromes

  Patients with von Hippel-Lindau, hereditary papillary RCC, or Birt-Hogg-Dubé syndromes develop multiple kidney tumours across their lifetime. Ablation preserves kidney tissue for management of future lesions — crucial for long-term function in these patients.

• Pre-Existing Chronic Kidney Disease

  Patients with CKD stage 3 or worse face progressive kidney function decline. Removing additional renal mass through surgery can tip them toward dialysis. MWA's minimal impact on remaining kidney function is preferable in these patients.

• Patient Preference for Minimally Invasive Treatment

  Some patients with surgically operable T1a RCC prefer the recovery profile and reduced invasiveness of ablation despite the slightly less established long-term evidence. This is a reasonable choice when discussed thoroughly with surgical and interventional teams.

Which renal masses are good candidates for MWA — and which ones favour alternative treatments.

For small renal masses, three options dominate: partial nephrectomy (the surgical standard), cryoablation (the more established ablation approach), and microwave ablation. Each has trade-offs.

Published outcomes from major series of MWA for small renal masses.

A typical kidney MWA procedure from preparation through recovery.

1. 1

   Step 1: Pre-Procedure Workup

   Recent multiphase CT or MRI for procedural planning. Renal function (eGFR, creatinine), coagulation tests, urine analysis. Biopsy may be done at a prior visit or at the start of the same session.

2. 2

   Step 2: Sedation and Positioning

   Patient positioned prone or lateral depending on tumour location. Conscious sedation typical, occasionally general anaesthesia. IV access established; vital signs monitored continuously.

3. 3

   Step 3: CT or Ultrasound Guidance

   Imaging guidance to precisely locate the tumour. Local anaesthetic at entry site. MWA antenna advanced through skin, retroperitoneal fat, and into the tumour under continuous imaging confirmation.

4. 4

   Step 4: Ablation Energy Delivery

   Microwave energy delivered for 5–10 minutes. Multiple antenna positions used for tumours >2 cm to ensure complete coverage with adequate margin (typically 5 mm beyond visible tumour edge).

5. 5

   Step 5: Post-Ablation Imaging

   Post-procedure contrast CT confirms complete ablation coverage and absence of immediate complications (bleeding, urine leak, adjacent organ injury). Brief tract ablation during antenna withdrawal prevents bleeding and tumour seeding.

6. 6

   Step 6: Recovery and Discharge

   Observation 4–6 hours post-procedure with serial vital signs and urine output monitoring. Most patients discharged same-day or after overnight stay. Mild flank discomfort and brief microscopic haematuria are common and self-limited.

Explore the full microwave ablation knowledge base.

Frequently Asked Questions

Common questions about microwave ablation for kidney cancer.